secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044760
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR
-----------------------------------------------------------------------------

- Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.
- Cash & equivalents $4.2M at Sept 30, 2024, up from $1.1M at Dec 31, 2023; $8.5M raised in equity financings.
- Awarded $14M multi-year NIH grant for PF614-MPAR; second Phase 1b trial initiated.
- Pivotal PF614 Phase 3 protocol submitted to FDA; feedback expected by end of November.
- Stockholders' equity $6.6M, compliant with Nasdaq $2.5M listing requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/0001493152-24-044760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer